A Senator Is Taking on the Pharma Companies Behind the Opioid Epidemic

Sen. Claire McCaskill (D-Mo.) is asking firms to hand over the materials they used to sell doctors on the drugs.

smartstock/Getty

Let our journalists help you make sense of the noise: Subscribe to the Mother Jones Daily newsletter and get a recap of news that matters.


On Tuesday, Sen. Claire McCaskill (D-Mo.) launched an investigation into how the nation’s leading painkiller manufacturers fueled the current opioid crisis—the most deadly drug epidemic in US history.

McCaskill requested internal sales and marketing materials, addiction studies, and details on compliance with governmental organizations from the top five opioid manufacturers: Purdue, Janssen/Johnson & Johnson, Insys, Mylan, and Depomed. If the companies refuse to comply, McCaskill would need support from her Republican colleagues on the Senate Homeland Security and Governmental Affairs Committee in order to subpoena the documents.

This is the most far-reaching Senate investigation into the opioid manufacturers to date, following a 2012 Senate Finance Committee investigation into payments to pain advocacy groups.

It comes at a time when drug overdoses are killing more Americans than car accidents or gun violence. Of the 52,000 overdose deaths in 2015, two-thirds were associated with opiates such as OxyContin, Vicodin, heroin, and fentanyl.

Experts trace the epidemic back to the early ’90s, when doctors started treating pain more aggressively. As I wrote last year:

Fueling the storm were pharmaceutical companies, which aggressively—and, in many cases, misleadingly—marketed painkillers to doctors and patients. Purdue Pharma, which introduced OxyContin in 1995, funded more than 20,000 pain-related educational programs between 1996 and 2002, according to an article last year in the Annual Review of Public Health.

Noting that doctors were wary of prescribing opioids because of concerns about addiction, the company funded studies finding that “physical dependence” on opioids is different from addiction and “clinically unimportant.”  It provided financial backing to the American Pain Society, which introduced the “Pain is the Fifth Vital Sign” campaign, and the Joint Commission, which accredits health care organizations, in addition to other physician and patient groups. Purdue Pharma and its executives were fined more than $600 million in 2007 after they were found guilty of misleading regulators, doctors, and patients about the drug’s addictive qualities.

“All of this didn’t happen overnight—it happened one prescription and marketing program at a time,” said McCaskill in a statement. “This investigation is about finding out whether the same practices that led to this epidemic still continue today, and if decisions are being made that harm the public health.”

THIS IS BIG FOR US.

And we won't beat around the bush: Our fundraising drive to finish our current budget on June 30 and start our new fiscal year on July 1 is lagging behind where we need it to be.

If you value the reporting you get from Mother Jones and you can right now, please consider joining your fellow readers with a donation to help make it all possible. Whether you can pitch in $5 or $500, it all matters.

If you're new to Mother Jones or aren't yet sold on supporting our nonprofit reporting, please take a moment to read Monika Bauerlein's post about our priorities after these chaotic several years, and why this relatively quiet moment is also an urgent one for our democracy and Mother Jones’ bottom line—and if you find it compelling, please join us.

payment methods

THIS IS BIG FOR US.

And we won't beat around the bush: Our fundraising drive to finish our current budget on June 30 and start our new fiscal year on July 1 is lagging behind where we need it to be.

If you value the reporting you get from Mother Jones and you can right now, please consider joining your fellow readers with a donation to help make it all possible. Whether you can pitch in $5 or $500, it all matters.

If you're new to Mother Jones or aren't yet sold on supporting our nonprofit reporting, please take a moment to read Monika Bauerlein's post about our priorities after these chaotic several years, and why this relatively quiet moment is also an urgent one for our democracy and Mother Jones’ bottom line—and if you find it compelling, please join us.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate